GENE ONLINE|News &
Opinion
Blog

2021-10-13| ChinaSpecial

Is the Race On for RNAi? A Chinese Pharma’s $450M Deal May Just Be the Start

by Joy Lin
Share To
siRNA, which operates via the RNA interference (RNAi) pathway, has the potential to silence disease-causing genes. When it is introduced into a cell, it assembles a “hit squad” -- an RNA-induced Silencing Complex (RISC) -- which looks for specific mRNA matching the siRNA's sequence. Once the target is found, the siRNA pairs with the mRNA, inducing cleavage. As the mRNA won't be translated into proteins, the action effectively puts a muffler on the gene that encodes the mRNA.

China's Hansoh Pharma believes the time is ripe to tap into gene silencing technology and has chosen to work with South Korea RNA Biotech OliX Pharmaceuticals in a deal worth over $450 million.

GO Prime with only $1.49 now

LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top